PAP
BCYC

Persistent Asset Partners’s Bicycle Therapeutics BCYC Stock Holding History

Persistent Asset Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Sell
117,254
-3,183
-3% -$14.6K 0.15% 112
2026
Q1 		$559K Buy
+120,437
New +$688K 0.21% 103

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Persistent Asset Partners's BCYC Position: Q2 2026 in Review

Persistent Asset Partners reduced its Bicycle Therapeutics (BCYC) stake by 2.6% in Q2 2026, selling an estimated $14.6K and leaving 117,254 shares worth $497K. The position accounts for 0.15% of the portfolio, ranked #112.

Persistent Asset Partners first reported a position in BCYC in Q1 2026 and has held it in 2 quarters since. The position peaked at $559K in Q1 2026. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Persistent Asset Partners held 117,254 shares of Bicycle Therapeutics worth $497K as of Q2 2026.
  • Persistent Asset Partners sold 3,183 Bicycle Therapeutics shares in Q2 2026, an estimated $14.6K.
  • Bicycle Therapeutics made up 0.15% of Persistent Asset Partners's portfolio in Q2 2026, its #112 holding.
  • Persistent Asset Partners first reported a position in Bicycle Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Persistent Asset Partners's Bicycle Therapeutics position peaked at $559K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.